Peptidomimetic inhibitors of PSMA, compounds comprising...

Details Peptidomimetic inhibitors of PSMA, compounds comprising... Peptidomimetic inhibitors of PSMA, compounds comprising...

2011-04-05

2011-04-05

Shiao, Rei-tsang (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C558S169000

Reissue Patent

active

RE042275

ABSTRACT:
Compounds of the formula, A—L—B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.

REFERENCES:
patent: 6372726 (2002-04-01), Slusher et al.
patent: 2004/0110723 (2004-06-01), Frangioni
Maung et al., “Molecular pruning studies on a phosphoramidate gamma-diglutamate analog inhibitor of prostate-specific membrane antigen; optimizing the potency of phenethylphosphonamidate inhibitors of prostate-specific membrane antigen,” 229th National Meeting of the American Chemical Society, vol. 229, Mar. 2005.
Tang et al., “Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase,” Biochemical and Biophysical Research Communications, 307(1):8-14 (2003).
Maung et al., “Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates,” Bioorganic & Medicinal Chemistry, 12(19):4969-4679 (2004).
Chen et al., “N-Phosphoryl Amino Acids and Peptides: Part V: O-Alkyl Substitution Effects on the 31P-NMR Spectra of Phosphoramidates,” Phosphorus, Sulfur and Silicon, 61:31-39 (1991).
Li et al., “Beta-Carboxyl Catalytic Effect of N-Phosphoryl Aspartic Acid,” Bioorganic Chemistry, 20:285-295 (1992).
Ng et al., “Synthesis of phosphoramidate and phosphoramidothionate inhibitors of prostate specific membrane antigen,” 220th National Meeting of the American Chemical Society, 220, Aug. 2000.
Etreby et al., “Induction of Apoptosis by Mifepristone and Tamoxifen in Human LNCaP Prostate Cancer Cells in Culture,” The Prostrate, 43(1):31-42 (2000).
Rodriguez et al., “Inhibition of Glutamate Carboxypeptidase II by Phosphonamidothionate Derivates of Glutamic Acid,” 16(4): 359-365 (2001).
Wone et al., “Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen,” Bioorganic & Medicinal Chemistry, 14(1):67-76 (2006).
Tino et al., “Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA),” Hybridoma, 19(3):249-257 (2000).
Barren et al., “Monoclonal Antibody 7E11.C5 Staining of Viable LNCAP Cells,” Prostate, 30(1):65-68 (1997).
Stefanic et al., “Aspartate and Glutamate Mimetic Structures in Biologically Active Compounds,” Current Medicinal Chemistry, 11, 945-968 (2004).
Maung et al., “Molecular pruning studies on a phosphoramidate gamma-diglutamate analog inhibitor of prostate-specific membrane antigen; optimizing the potency of phenethylphosphonamidate inhibitors of prostate-specific membrane antigen,” poster presented Mar. 14, 2005, at the 229th National Meeting of the American Chemical Society, San Diego, CA.

Affiliated with

Also associated with

Rating

Peptidomimetic inhibitors of PSMA, compounds comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptidomimetic inhibitors of PSMA, compounds comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidomimetic inhibitors of PSMA, compounds comprising... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2628174